Evoxac

openFDA label record#

This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.

Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)

Brand name
Evoxac
Generic name
CEVIMELINE HYDROCHLORIDE
Manufacturer
Cosette Pharmaceuticals, Inc.
Product type
HUMAN PRESCRIPTION DRUG
SPL set ID
dac32a9b-05b8-42c2-9a29-d885a9279456
SPL ID
5fdb2294-e353-0887-e063-6394a90ad0a2
Version
3
Effective date
2026-11-09
Source export date
2026-11-13
Source partition
6
Source file
https://download.open.fda.gov/drug/label/drug-label-0006-of-0014.json.zip
Source object key
raw/openfda/drug-label/2026-11-13/a79c47b73cf1c0b9829667844daa083c5114cf268a1839f963bc5617e9060c4f/drug-label-0006-of-0014.json.zip
Source manifest SHA-256
8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
Import run
20261116T150851Z
Imported at
2026-11-16 16:20:43
Harmonized routes table
Harmonized routes
ORAL

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Warnings sections page 1 of 1 · 1 matching rows.

warnings and cautions

5 WARNINGS AND PRECAUTIONS Cardiovascular Adverse Reactions: EVOXAC can alter cardiac conduction and/or heart rate. Monitor patients with a history of atrial fibrillation or cardiovascular disease. ( 5.1 ) Pulmonary Adverse Reactions: EVOXAC can increase airway resistance, bronchial smooth muscle tone, and bronchial secretions. Monitor patients with controlled asthma, chronic bronchitis, or chronic obstructive pulmonary disease. ( 5.2 ) Ophthalmic Adverse Reactions: Advise caution while driving or performing hazardous activities. ( 5.3 ) Cholinergic Adverse Reactions: Monitor patients for adverse reactions related to EVOXAC’s cholinergic effects. Closely monitor patients with a history of nephrolithiasis or cholelithiasis ( 5.4 ) 5.1 Cardiovascular Adverse Reactions EVOXAC can alter cardiac conduction and/or heart rate. Monitor patients with a history of atrial fibrillation or cardiovascular disease during treatment with EVOXAC. 5.2 Pulmonary Adverse Reactions EVOXAC can increase airway resistance, bronchial smooth muscle tone, and bronchial secretions. Monitor patients with controlled asthma, chronic bronchitis, or chronic obstructive pulmonary disease during treatment with EVOXAC. 5.3 Ophthalmic Adverse Reactions EVOXAC may cause ophthalmic adverse reactions. Topical ophthalmic dosage forms of muscarinic agonists have been reported to cause visual blurring which may result in decreased visual acuity (especially at night and in patients with central lens changes) and impairment of depth perception. EVOXAC is not approved for topical ophthalmic use. Advise caution while driving or performing hazardous activities. 5.4 Cholinergic Adverse Reactions EVOXAC is a cholinergic agonist and can cause adverse reactions related to its cholinergic effects. Monitor patients for adverse reactions related EVOXAC’s cholinergic effects which may include headache, visual disturbance, lacrimation, sweating, respiratory distress, gastrointestinal spasm, nausea, vomiting, diarrhea, atrioventricular block, tachycardia, bradycardia, hypotension, hypertension, shock, mental confusion, cardiac arrhythmia, and tremors. Hyperhidrosis leading to dehydration may occur. If hyperhidrosis occurs, advise patients to keep hydrated and inform their healthcare provider. Contractions of the gallbladder or biliary smooth muscle may occur which could precipitate complications such as cholecystitis, cholangitis and biliary obstruction. An increase in the ureteral smooth muscle tone may occur which could precipitate renal colic or ureteral reflux in patients with nephrolithiasis. Closely monitor patients with a history of nephrolithiasis or cholelithiasis during treatment with EVOXAC.

Adverse reactions cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Adverse reactions sections page 1 of 1 · 2 matching rows.

adverse reactions

6 ADVERSE REACTIONS The most common (incidence ≥ 3 %) adverse reactions observed with EVOXAC capsules having equal or greater incidence than placebo are excessive sweating, nausea, sinusitis, upper respiratory tract infection, rhinitis, abdominal pain, urinary tract infection, coughing, vomiting, injury, back pain, bronchitis, arthralgia, and fatigue. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Cosette Pharmaceuticals, Inc. at 1-800-922-1038 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The safety of EVOXAC capsules was evaluated in placebo-controlled trials (Trials 1, 2, and 3) conducted in the U.S. that enrolled 320 adult subjects with Sjögren’s disease who received EVOXAC capsules dosages ranging from 15 mg three times a day (0.5 times the approved recommended dosage) to 60 mg three times a day (2 times the approved recommended dosage) [see Clinical Studies ( 14 )] . In these trials, 14.6% of subjects discontinued treatment with EVOXAC capsules due to adverse events. Although dosages ranging from 15 mg three times a day to 60 mg three times a day were evaluated in these trials, the recommended dosage of EVOXAC capsules is 30 mg three times a day [see Dosage and Administration ( 2 )] . The safety of EVOXAC oral solution was established from these trials of EVOXAC capsules [see Clinical Pharmacology (12.3)] . Table 1 shows the adverse reactions that were observed with EVOXAC capsules 30 mg three times a day compared to placebo in the clinical trials. Table 1: Adverse Reactions Reported in ≥ 3% of EVOXAC Capsules-Treated Subjects and More Frequently than Placebo-Treated Subjects Adverse Reaction EVOXAC Capsules 30 mg Three Times a Day n * =533 Placebo Three Times a Day n=164 Excessive Sweating 18.7% 2.4% Nausea 13.8% 7.9% Sinusitis 12.3% 10.9% Upper Respiratory Tract Infection 11.4% 9.1% Rhinitis 11.2% 5.4% Abdominal Pain 7.6% 6.7% Urinary Tract Infection 6.1% 3.0% Coughing 6.1% 3.0% Vomiting 4.6% 2.4% Injury 4.5% 2.4% Back Pain 4.5% 4.2% Bronchitis 4.1% 1.2% Arthralgia 3.7% 1.8% Fatigue 3.3% 1.2% * n is the total number of patients exposed to the dose at any time during the trial. The following events were reported in Sjögren’s patients at incidences of <3% and ≥1%: skeletal pain, insomnia, hot flushes, rigors, anxiety, constipation, tremor, abnormal vision, hypertonia, peripheral edema, chest pain, myalgia, fever, anorexia, eye pain, earache, dry mouth, vertigo, salivary gland pain, pruritus, influenza-like symptoms, eye infection, post operative pain, vaginitis, skin disorder, depression, hiccup, hyporeflexia, infection, fungal infection, sialadenitis, otitis media, erythematous rash, pneumonia, edema, salivary gland enlargement, allergy, gastroesophageal reflux, eye abnormality, migraine, tooth disorder, epistaxis, flatulence, toothache, ulcerative stomatitis, anemia, hypoesthesia, cystitis, leg cramps, abscess, eructation, moniliasis, palpitation, increased amylase, xerophthalmia, allergic reaction. 6.2 Postmarketing Experience The following adverse reactions have been identified during post approval use of EVOXAC. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Gastrointestinal disorders: Diarrhea, excessive salivation, dyspepsia, pancreatitis General disorders: Asthenia Immune system disorders: Anaphylactic reaction Musculoskeletal disorders: Pain in extremity Nervous system disorders: Headache, dizziness Respiratory disorders: Pharyngitis (nasopharyngitis) Vascular disorders: Flushing Skin and subcutaneous tissue disorders: Rash, Stevens-Johnson syndrome

adverse reactions table

<table width="100%" border="1" cellspacing="0" cellpadding="0"> <thead> <tr> <td> <paragraph> <content styleCode="bold">Adverse Reaction</content> </paragraph> </td> <td valign="bottom"> <paragraph> <content styleCode="bold">EVOXAC Capsules 30 mg </content> </paragraph> <paragraph> <content styleCode="bold">Three Times a Day</content> </paragraph> <paragraph> <content styleCode="bold">n <sup>*</sup>=533 </content> </paragraph> </td> <td> <paragraph> <content styleCode="bold">Placebo</content> </paragraph> <paragraph> <content styleCode="bold">Three Times a Day n=164 </content> </paragraph> </td> </tr> </thead> <tbody> <tr> <td> <paragraph>Excessive Sweating</paragraph> </td> <td> <paragraph>18.7%</paragraph> </td> <td> <paragraph>2.4%</paragraph> </td> </tr> <tr> <td> <paragraph>Nausea</paragraph> </td> <td> <paragraph>13.8%</paragraph> </td> <td> <paragraph>7.9%</paragraph> </td> </tr> <tr> <td valign="top"> <paragraph>Sinusitis</paragraph> </td> <td valign="top"> <paragraph>12.3%</paragraph> </td> <td valign="top"> <paragraph>10.9%</paragraph> </td> </tr> <tr> <td valign="top"> <paragraph>Upper Respiratory Tract Infection</paragraph> </td> <td valign="top"> <paragraph>11.4%</paragraph> </td> <td valign="top"> <paragraph>9.1%</paragraph> </td> </tr> <tr> <td> <paragraph>Rhinitis</paragraph> </td> <td> <paragraph>11.2%</paragraph> </td> <td> <paragraph>5.4%</paragraph> </td> </tr> <tr> <td> <paragraph>Abdominal Pain</paragraph> </td> <td> <paragraph>7.6%</paragraph> </td> <td> <paragraph>6.7%</paragraph> </td> </tr> <tr> <td> <paragraph>Urinary Tract Infection</paragraph> </td> <td> <paragraph>6.1%</paragraph> </td> <td> <paragraph>3.0%</paragraph> </td> </tr> <tr> <td> <paragraph>Coughing</paragraph> </td> <td> <paragraph>6.1%</paragraph> </td> <td> <paragraph>3.0%</paragraph> </td> </tr> <tr> <td> <paragraph>Vomiting</paragraph> </td> <td> <paragraph>4.6%</paragraph> </td> <td> <paragraph>2.4%</paragraph> </td> </tr> <tr> <td> <paragraph>Injury</paragraph> </td> <td> <paragraph>4.5%</paragraph> </td> <td> <paragraph>2.4%</paragraph> </td> </tr> <tr> <td> <paragraph>Back Pain</paragraph> </td> <td> <paragraph>4.5%</paragraph> </td> <td> <paragraph>4.2%</paragraph> </td> </tr> <tr> <td> <paragraph>Bronchitis</paragraph> </td> <td> <paragraph>4.1%</paragraph> </td> <td> <paragraph>1.2%</paragraph> </td> </tr> <tr> <td> <paragraph>Arthralgia</paragraph> </td> <td> <paragraph>3.7%</paragraph> </td> <td> <paragraph>1.8%</paragraph> </td> </tr> <tr> <td> <paragraph>Fatigue</paragraph> </td> <td> <paragraph>3.3%</paragraph> </td> <td> <paragraph>1.2%</paragraph> </td> </tr> </tbody> </table>

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.